Lexeo Therapeutics is a clinical-stage genetic medicine company developing gene therapy candidates for genetic cardiovascular conditions and central nervous system disorders. The company focuses on addressing the underlying genetic causes of diseases such as Friedreich ataxia cardiomyopathy, arrhythmogenic cardiomyopathy, and hypertrophic cardiomyopathy. Its pipeline includes LX2006 for Friedreich ataxia cardiomyopathy, LX2020 for PKP2-associated arrhythmogenic cardiomyopathy, LX2021 for connexin 43-related cardiac disorders, and LX2022 for TNNI3-related hypertrophic cardiomyopathy. Lexeo utilizes the AAVrh10 vector for intravenous delivery to target myocardial cells. The company also holds rights to LX1001, a candidate for APOE4-associated Alzheimer's disease, which has completed Phase 1/2 clinical trials. Lexeo retains exclusive worldwide development and commercialization rights to its product candidates and is seeking business development opportunities for its Alzheimer's disease portfolio.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage lexeotx.com
Sector Healthcare IR page ir.lexeotx.com
Tags
gene therapy, cardiovascular diseases, friedreich ataxia, arrhythmogenic cardiomyopathy, hypertrophic cardiomyopathy, aavrh10 vector, rare diseases, central nervous system, alzheimer's disease, LX2006, LX2020, LX2021, LX2022, LX1001
Press page —

Metrics

Valuation  
Market cap $ 269.882M
Market cap (USD) $ 269.882M
P/E -3.54
PEG —
P/BV 1.25
P/S 412.66
P/OCF -3.09
P/FCF -2.73
Dividend yield —
Turnover / mcap —
Returns  
ROE -55.0%
ROI -54.3%
ROIC -44.5%
Profit margin —
Growth  
Revenue growing No
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 49
Quality score -78.6%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue — — — 654K 1.657M 0
Net profit -99.961M -98.333M -66.394M -59.277M -50.622M 0
Free cash flow -98.958M -81.632M -59.611M -55.461M -44.37M —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Share price 9.93 6.58 13.42 — — —
Price performance 12m 0.51 -0.51 — — — —

Filed figures

Figure Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Lease liabilities (USD) — 13.5M 11.6M 9.92M 7.89M
Cash and deposits (USD) 136M 77.3M 121M 35M 63M
Right-of-use assets (USD) — 10.7M 9.44M 8.07M 6.58M
Cash flow detail
Operating cash flow (USD) — -54.6M -59.5M -81.2M -98.6M
Purchases of property, plant and equipment (USD) — -672,000 -115,000 -481,000 -397,000
Change in payables (cash effect) (USD) — -426,000 -180,000 2.38M -1.56M
Interest paid (cash effect) (USD) — -77,000 -176,000 -127,000 -104,000
Income taxes paid (cash effect) (USD) — — — -133,000 -551,000
Share-based compensation (USD) — 1.78M 3.04M 12.5M 12.1M
Free cash flow (OCF - PPE - intangibles) (USD) — -55.2M -59.6M -81.6M -99M
Income detail
Research and development expense (USD) — 49.2M 53.1M 74.1M 63.8M
Total comprehensive income (USD) — — -66.4M -98.4M -99.7M
Comprehensive income to owners (USD) — — -66.4M -98.4M -99.7M
Reported Dec 11, 2023 Mar 11, 2024 Mar 24, 2025 Mar 30, 2026 Mar 30, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Participants in high-dose cohorts achieved 80% mean reduction in non-sustained ventricular tachycardia and

44% mean reduction in premature ventricular contractions at latest assessment

LX2020 generally well tolerated across 10 participants with no clinically significant complement activation

U.S. Food and Drug Administration open to guideline-defined non-sustained ventricular tachycardia as a primary surrogate endpoint to support potential accelerated approval of LX2020

Cash, cash equivalents and investments of $219.1 million expected to provide operational runway into 2028

Company to host webcast today at 8:00 AM ET

NEW YORK – November 16, 2026 (GLOBE NEWSWIRE) – Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, today announced positive interim data from the ongoing HEROIC-PKP2 Phase I/II clinical trial of LX2020 for the treatment of PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM).

October 19, 2026

PDF Version

NEW YORK, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO) a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, today announced that it will host an educational investor event, “Assessing clinically meaningful arrhythmias in PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM)” on Wednesday, October 21, 2026 at 1:00 PM ET.

The event will feature a discussion with Narinder Bhalla, M.D., Chief Medical Officer of Lexeo Therapeutics, on the clinical significance of key assessments used in PKP2-ACM, including the evidence supporting their relevance for evaluating disease burden and treatment response, as well as guideline-based approaches for measurement.

He will be joined by Alessio Gasperetti, M.D., Ph.D., a physician-scientist at the Cleveland Clinic specializing in inherited arrhythmia syndromes, cardiomyopathies, ventricular arrhythmias, and sudden cardiac death risk stratification. His research focuses on improving diagnosis, risk assessment, and treatment strategies for patients with genetic and structural heart disease and has helped advance the understanding of the natural history of PKP2-ACM including disease progression, arrhythmic burden, clinical outcomes and treatment response under current standards of care. Dr. Gasperetti received his medical degree from the University of Milan and completed post-doctoral fellowships in arrhythmogenic right ventricular cardiomyopathy (ARVC) at University Hospital Zurich and the Johns Hopkins University. He earned his Ph.D. in cardiology from Utrecht University and has authored or co-authored more than 150 scientific publications spanning arrhythmogenic cardiomyopathy, ventricular arrhythmias, and electrophysiology.

The event will be webcast live under the Events & Presentations tab in the Investors section of the Company’s website. A replay of the webcast will be available on the Lexeo website following the presentation.

About Lexeo Therapeutics Lexeo Therapeutics is a New York City-based, clinical stage company dedicated to reshaping the path of genetic disease. By advancing pioneering science, Lexeo seeks to set a new standard in the treatment of cardiovascular and neurological genetic diseases, charting the path to patient outcomes once thought out of reach. The Company is advancing a portfolio of therapeutic candidates designed to address the underlying genetic causes of disease, including LX2006 for Friedreich ataxia (FA), LX2020 for plakophilin-2 (PKP2) arrhythmogenic cardiomyopathy, and others in devastating diseases with high unmet need.

Media Response: [email protected]

Investor Response: Ashley Kaplowitz [email protected]

Contact Us

  • Investor Inquiries

Investor Inquiries

[email protected]

  • Media Inquiries

Media Inquiries

[email protected]

  • Print page

Print page

  • [Email alerts

Email alerts](https://ir.lexeotx.com/resources/email-alerts)

October 8, 2026

PDF Version

NEW YORK, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO) a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, today announced that the Company will participate in a fireside chat at Chardan’s 10th Annual Healthcare Conference on October 20, 2026 at 9:30am ET.

The event will be webcast live under the Events & Presentations tab in the Investors section of the Company’s website. A replay of the webcast will be available on the Lexeo website following the presentation.

About Lexeo Therapeutics Lexeo Therapeutics is a New York City-based, clinical stage company dedicated to reshaping the path of genetic disease. By advancing pioneering science, Lexeo seeks to set a new standard in the treatment of cardiovascular and neurological genetic diseases, charting the path to patient outcomes once thought out of reach. The Company is advancing a portfolio of therapeutic candidates designed to address the underlying genetic causes of disease, including LX2006 for Friedreich ataxia (FA), LX2020 for plakophilin-2 (PKP2) arrhythmogenic cardiomyopathy, and others in devastating diseases with high unmet need.

Media Response: [email protected]

Investor Response: Ashley Kaplowitz [email protected]

Contact Us

  • Investor Inquiries

Investor Inquiries

[email protected]

  • Media Inquiries

Media Inquiries

[email protected]

  • Print page

Print page

  • [Email alerts

Email alerts](https://ir.lexeotx.com/resources/email-alerts)

Prompts

Lexeo Therapeutics, Inc. (ticker LXEO), listed in United States.

ETFs Holding Lexeo Therapeutics, Inc.

ETF Weight in ETF Shares Market value As of
FSEV 0.07% 937 $ 4,361.74 Jun 30, 2026
FEAC 0.04% 2,438 $ 11.349K Jun 30, 2026
RESM 0.01% 72 $ 335.16 Jun 30, 2026
FESM 0.01% 77,459 $ 360.572K Jun 30, 2026
DFAS 0.00% 506,145 $ 1.473M Nov 12, 2026
DFAC 0.00% 235,187 $ 684.394K Nov 12, 2026
DXUV 0.00% 16,064 $ 46.746K Nov 12, 2026
DCOR 0.00% 50,466 $ 146.856K Nov 12, 2026
AVSC 0.00% 30,553 $ 98.686K Nov 16, 2026